Evidence map›Paper›PMID 30151896›Full record

ArticleInternational journal of cancer2019

Redefining synchronous colorectal cancers based on tumor clonality.

José Perea, Juan L García, Luis Corchete, Eva Lumbreras, María Arriba, Daniel Rueda, Sandra Tapial, Jessica Pérez, Victoria Vieiro, Yolanda Rodríguez and 6 more

Abstract read
In one paragraph

Article in International journal of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 2 countries.

José PereaSurgery Department, Fundación Jiménez Díaz University Hospital, Madrid, Spain.ORCID 0000-0001-5522-8844
Juan L GarcíaBiomedical Research Institute of Salamanca (IBSAL), University Hospital of Salamanca-USAL-CSIC, Salamanca, Spain.
Luis CorcheteBiomedical Research Institute of Salamanca (IBSAL), University Hospital of Salamanca-USAL-CSIC, Salamanca, Spain.
Eva LumbrerasBiomedical Research Institute of Salamanca (IBSAL), University Hospital of Salamanca-USAL-CSIC, Salamanca, Spain.
María ArribaBiochemistry Department, Gregorio Marañón University Hospital, Madrid, Spain.ORCID 0000-0001-6516-643X
Daniel RuedaCentre for Biomedical Research of the 12 de Octubre University Hospital, Madrid, Spain.
Sandra TapialCentre for Biomedical Research of the 12 de Octubre University Hospital, Madrid, Spain.
Jessica PérezBiomedical Research Institute of Salamanca (IBSAL), University Hospital of Salamanca-USAL-CSIC, Salamanca, Spain.
Victoria VieiroSurgery Department, 12 de Octubre University Hospital, Madrid, Spain.
Yolanda RodríguezDepartment of Pathology, 12 de Octubre University Hospital, Madrid, Spain.
Lorena BrandárizSurgery Department, Fundación Jiménez Díaz University Hospital, Madrid, Spain.
Mariano García-ArranzHealth Research Institute Fundación Jiménez Díaz, Madrid, Spain.
Damián García-OlmoSurgery Department, Fundación Jiménez Díaz University Hospital, Madrid, Spain.
Ajay GoelCenter for Gastrointestinal Research, Center for Translational Genomics and Oncology, Baylor Scott & White Research Institute, Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, TX.
Miguel UriosteFamilial Cancer Clinical Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Rogelio González SarmientoBiomedical Research Institute of Salamanca (IBSAL), University Hospital of Salamanca-USAL-CSIC, Salamanca, Spain.
Universidad de Salamanca · ESHospital Universitario Fundación Jiménez Díaz · ESResearch Institute Hospital 12 de Octubre · ESBaylor University Medical Center · USHospital General Universitario Gregorio Marañón · ESInstituto de Salud Carlos III · ES

Funding

The Biology and Diagnosis of HNPCCR01CA072851 · NCI · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI GOEL, AJAY · 1996 to 2019
$6.6M
Aspirin and Cancer Prevention in Lynch Syndrome: From Cell to Population DataU01CA187956 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI GOEL, AJAY, WODARZ, DOMINIK F · 2014 to 2018
$2.7M
MicroRNA Biomarkers for Determining Treatment Response in Colorectal CancerR01CA202797 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI GOEL, AJAY · 2016 to 2020
$1.9M
Development of microRNA Biomarkers For Noninvasive Detection of Colorectal CancerR01CA184792 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI GOEL, AJAY · 2015 to 2019
$1.8M
METHYLATION BIOMARKER DEVELOPMENT FOR NONINVASIVE DETECTION OF COLORECTAL CANCERR01CA181572 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI GOEL, AJAY · 2014 to 2018
$1.6M
NCI NIH HHS R01 CA072851NCI NIH HHS R01 CA181572NCI NIH HHS R01 CA184792NCI NIH HHS R01 CA202797NCI NIH HHS U01 CA187956
6 · The paper itself

Abstract

To analyze the possible clonal origin of a part of Synchronous colorectal cancer (SCRC), we studied 104 paired-SCRCs from 52 consecutive patients without hereditary forms of CRC. We used a Single-Nucleotide Polymorphism array to characterize the genomic profiles, and subsequently used a statistical application to define them according to clonality within the same individual. We categorized the ensuing groups according to colonic location to identify differential phenotypes. The SCRC Monoclonal group (M) (19 cases) was divided into Monosegmental (MM) and Pancolonic (MP) groups. The SCRC Polyclonal group (P) (33 cases) was also divided into Monosegmental (PM) and Pancolonic (PP), the first exhibiting preference for left colon. The MM group showed a high rate of mucinous tumors, the lowest mean-number of tumors and associated-polyps, and the worst prognosis. The MP group included the largest mean-number of associated-polyps, best prognosis and familial cancer component. The PM group seemed to be a "frontier" group. Finally, the PP group also exhibited a mucin component, the highest mean-number of tumors (4.6) compared with the mean-number of polyps (7.7), poor prognosis and sporadic cases. Most relevant differential genomic regions within M groups were gains on 1q24 and 8q24, and deletions on 1p21 and 1p23 for MM, while within P were the gains on 7q36 and deletions on 1p36 for PM. The statistical application employed seems to define clonality more accurately in SCRC -more likely to be polyclonal in origin-, and together with the tumor locations, helped us to configure a classification with prognostic and clinical value.

Indexed as

Polymorphism, Single NucleotideAgedAged, 80 and overClonal EvolutionColorectal NeoplasmsFemaleHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedNeoplasms, Multiple PrimaryPrognosisWhole Genome Sequencingclonalitycolon locationmonoclonalpolyclonalSingle-Nucleotide Polymorphism array (SNP array)Synchronous colorectal cancer

Identifiers

PMID30151896
PMCPMC6361712
OpenAlexW2889653401

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.